Drug intelligence / Profile preview

BL-ARC001

Development stage: Unknown
Lead developer: Biokin Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BL-ARC001 is a bispecific antibody-drug conjugate (ADC) developed by Biokin Pharmaceutical (Sichuan Baili Pharmaceutical) using its proprietary HIRE-ARC platform. While the specific binding targets remain undisclosed, the molecule is designed to deliver a cytotoxic payload to tumor cells by targeting two distinct antigens simultaneously. It is currently in early development for the treatment of various solid tumors, including lung cancer, breast cancer, head and neck cancer, and gastrointestinal tumors. The HIRE-ARC platform is intended to produce next-generation ADCs with reduced toxicity and enhanced efficacy.

Beyond the preview

Go deeper on BL-ARC001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-ARC001.

Explore the full profile